Eton Pharma Announces ET-900 Clinical Program for Infantile & Epileptic Spasms
Eton Pharmaceuticals announced the ET-900 program, an Investigational New Drug (IND) application for mecasermin in refractory epileptic spasms, leveraging research from Baylor College of Medicine seeking to address the high resistance rates of current epileptic spasms therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed